• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Leap Therapeutics Inc. (Amendment)

    2/14/22 4:05:15 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LPTX alert in real time by email
    SC 13G/A 1 p22-0122sc13ga.htm LEAP THERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No.  1)*
     

    Leap Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    52187K101

    (CUSIP Number)
     

    December 31, 2021

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 52187K101 13G/APage 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    HHLR Advisors, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

    6

    SHARED VOTING POWER

    -0-

    7

    SOLE DISPOSITIVE POWER

    -0-

    8

    SHARED DISPOSITIVE POWER

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    -0-

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

     

     

    CUSIP No. 52187K101 13G/APage 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Leap Therapeutics, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
      The Company's principal executive office is located at 47 Thorndike St, Suite B1-1, Cambridge, MA 02141.

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by HHLR Advisors, Ltd., an exempted Cayman Islands company (“HHLR” or the “Reporting Person”), with respect to the shares of Common Stock (as defined in Item 2(d) below) held by HHLR Fund, L.P. ("HHLR Fund") and YHG Investment, L.P. (“YHG”, together with HHLR Fund, the “Hillhouse Entities”).  HHLR acts as the sole investment manager of each of HHLR Fund and YHG.  HHLR is hereby deemed to be the sole beneficial owner of, and to solely control the voting and investment power of, the shares of Common Stock held by the Hillhouse Entities.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of the Reporting Person is Office #122, Windward 3 Building, Regatta Office Park, West Bay Road, Grand Cayman, Cayman Islands, KY1-9006.

     

    Item 2(c). CITIZENSHIP
      Cayman Islands

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, par value $0.001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER
      52187K101

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ý An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

     

     

    CUSIP No. 52187K101 13G/APage 4 of 5 Pages

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: ___________________________________

     

    Item 4. OWNERSHIP
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for the Reporting Person and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 52187K101 13G/APage 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 14, 2022

     

    HHLR ADVISORS, LTD.  
       
       
    /s/ Richard A. Hornung  
    Name:  Richard A. Hornung  
    Title:    General Counsel and Chief Compliance Officer  

     

     

    Get the next $LPTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LPTX

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Neutral
    H.C. Wainwright
    1/29/2025$9.00 → $1.25Outperform → Neutral
    Robert W. Baird
    6/28/2024$8.00Buy
    Rodman & Renshaw
    10/4/2021$6.00Buy
    Mizuho
    9/14/2021$3.00 → $4.00Outperform
    Raymond James
    More analyst ratings

    $LPTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Leap Therapeutics Reports First Quarter 2025 Financial Results

      CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025. Leap Highlights: Reported positive data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC) patients demonstrating significantly higher overall response rate (ORR) and longer progression-free survival (PFS) across DKK1-high and VEGF-naïve subgroupsHosted virtual key opinion leader (KOL) event featuring Zev A. Wainberg, MD, to further discuss the

      5/13/25 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Purple Biotech Appoints Shai Lankry as Chief Financial Officer

      U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today the appointment of Shai Lankry as its Chief Financial Officer. "We are pleased to welcome Shai on board. His extensive experience in the U.S. and European biotech and pharma marke

      5/12/25 7:30:00 AM ET
      $GMDA
      $LPTX
      $PPBT
      $WST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

      FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois. FL-501 is a potential best-in-class monoclonal antibody targeting growth differentiation factor 15 (GDF-15), a cytokine that is impli

      4/25/25 1:00:00 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    SEC Filings

    See more
    • Leap Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

      5/13/25 7:10:27 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Leap Therapeutics Inc.

      10-Q - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

      5/13/25 6:51:44 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Leap Therapeutics Inc.

      DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

      4/25/25 8:54:12 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO,CFO,Pres.,GC,Treas.&Sec. Onsi Douglas E converted options into 32,500 shares, increasing direct ownership by 44% to 106,146 units (SEC Form 4)

      4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

      4/1/25 9:55:11 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Head of Reg Affairs/Qual Granfield Christine converted options into 22,500 shares and covered exercise/tax liability with 6,604 shares (SEC Form 4)

      4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

      4/1/25 9:54:08 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Baum Jason covered exercise/tax liability with 6,604 shares and converted options into 22,500 shares (SEC Form 4)

      4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

      4/1/25 9:53:26 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leap Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral

      1/29/25 7:15:39 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leap Therapeutics downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously

      1/29/25 7:15:19 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Leap Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00

      6/28/24 8:18:39 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Leap Therapeutics Inc.

      SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

      11/14/24 6:07:56 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Leap Therapeutics Inc.

      SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

      4/25/24 8:39:23 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Leap Therapeutics Inc.

      SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

      4/19/24 4:31:26 PM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

      CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. "We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a

      9/6/22 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LPTX
    Financials

    Live finance-specific insights

    See more
    • Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

      Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024. Leap Highlights: Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) in second-line patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) confirming:Statistically significant 32% higher overall response rate (ORR), 3.5 month longer progression-free survival (P

      3/26/25 7:05:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

      Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, g

      3/26/25 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

      35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., Jan.

      1/28/25 7:00:00 AM ET
      $LPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care